Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1582-1590

  Brownell, Jessica ^c   Bruckner, Jacob ^a   Wagoner, Jessica ^a   Thomas, Emmanuel ^b   Loo, Yueh Ming ^c   Gale Jr , Michael ^c   Liang, T Jake ^d   Polyak, Stephen J ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d National Institute of Diabetes and Digestive and Kidney Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR AP 1; VIRUS RNA;

ARTICLE; BINDING SITE; CELL NUCLEUS; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INTERFERON STIMULATED RESPONSE ELEMENT; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; VIRUS GENOME;

CELL LINE, TUMOR; CHEMOKINE CXCL10; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERONS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; TOLL-LIKE RECEPTOR 3; TRANSCRIPTIONAL ACTIVATION;

EID: 84892449850     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02007-13     Document Type: Article

References (65)

1. Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140:805-820. http://dx.doi.org/10.1016/j.cell.2010.01.022.
2. Eksioglu EA, Zhu H, Bayouth L, Bess J, Liu H-Y, Nelson DR, Liu C. 2011. Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells. PLoS One 6:e21186. http://dx.doi.org/10.1371/journal .pone.0021186.
3. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. 2004. HepatitisCcore and nonstructural 3 proteins trigger Toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127:1513-1524. http://dx.doi.org/10.1053/j.gastro.2004.08.067.
4. Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM. 2012. Activation of chemokine and inflammatory cytokine response in hepatitis C virusinfected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 55:666-675. http://dx.doi.org/10.1002/hep.24763.
5. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M. 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454:523-527. http://dx.doi.org/10.1038/nature07106.
6. Ank N, West H, Paludan SR. 2006. IFN-lambda: novel antiviral cytokines. J. Interferon Cytokine Res. 26:373-379. http://dx.doi.org/10.1089/jir.2006.26.373.
7. Kawai T, Akira S. 2008. Toll-like receptor and RIG-1-like receptor signaling. Ann. N. Y. Acad. Sci. 1143:1-20. http://dx.doi.org/10.1196/annals .1443.020.
8. Aaronson DS, Horvath CM. 2002. A road map for those who don't know JAK-STAT. Science 296:1653-1655. http://dx.doi.org/10.1126/science .1071545.
9. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163-189. http://dx.doi.org/10.1189/jlb.0603252.
10. Banerjee A, Gerondakis S. 2007. Coordinating TLR-activated signaling pathways in cells of the immune system. Immunol. Cell Biol. 85:420-424. http://dx.doi.org/10.1038/sj.icb.7100098.
11. Yu M, Levine SJ. 2011. Toll-like receptor 3, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev. 22:63-72. http://dx.doi.org/10.1016/j.cytogfr.2011.02.001.
12. Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BRG, Li X. 2003. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptorassociated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J. Biol. Chem. 278:16713-16719. http://dx.doi.org/10.1074/jbc.M300562200.
13. Mikkelsen SS, Jensen SB, Chiliveru S, Melchjorsen J, Julkunen I, Gaestel M, Arthur JSC, Flavell RA, Ghosh S, Paludan SR. 2009. RIG-Imediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1. J. Biol. Chem. 284:10774-10782. http://dx.doi.org/10.1074/jbc.M807272200.
14. Whitmarsh AJ, Davis RJ. 1996. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:589-607. http://dx.doi.org/10.1007/s001090050063.
15. Yang S-H, Sharrocks AD, Whitmarsh AJ. 2013. MAP kinase signalling cascades and transcriptional regulation. Gene 513:1-13. http://dx.doi.org/10.1016/j.gene.2012.10.033.
16. Kalvakolanu DV, Roy SK. 2005. CCAAT/enhancer binding proteins and interferon signaling pathways. J. Interferon Cytokine Res. 25:757-769. http://dx.doi.org/10.1089/jir.2005.25.757.
17. Spurrell JCL, Wiehler S, Zaheer RS, Sanders SP, Proud D. 2005. Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L85-L95. http://dx.doi.org/10.1152/ajplung.00397.2004.
18. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH. 2008. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48:1440-1450. http://dx.doi.org/10.1002/hep.22500.
19. Larrubia J-R, Calvino M, Benito S, Sanz-de-Villalobos E, Perna C, Pérez-Hornedo J, González-Mateos F, García-Garzón S, Bienvenido A, Parra T. 2007. The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J. Hepatol. 47:632-641. http://dx.doi.org/10.1016/j.jhep.2007.04.009.
20. Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH, Hudson ML, Howell CD, Talloen W, Bollekens J, De Wit M, Scholliers A, Fried MW. 2011. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53:14-22. http://dx.doi.org/10 .1002/hep.24056.
21. Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky J-M, Haagmans BL, Zeuzem S, Bochud P-Y, Hellstrand K, DITTOHCV Study Group. 2011. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 6:e17232. http://dx.doi.org/10.1371/journal.pone.0017232.
22. Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky J-M, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M, DITTO-HCV and NOR DynamIC Study Groups. 2010. Systemic and intrahepatic interferon-gammainducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 51:1523-1530. http://dx.doi.org/10.1002/hep.23509.
23. Wagoner J, Austin M, Green J, Imaizumi T, Casola A, Brasier A, Khabar KSA, Wakita T, Gale M, Polyak SJ. 2007. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J. Virol. 81:309-318. http://dx.doi.org/10.1128/JVI.01411-06.
24. Bonizzi G, Karin M. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280-288. http://dx.doi.org/10.1016/j.it.2004.03.008.
25. Baeuerle PA, Baltimore D. 1988. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242:540-546. http://dx.doi.org/10.1126/science.3140380.
26. Kanarek N, Ben-Neriah Y. 2012. Regulation of NF-κB by ubiquitination and degradation of the IκBs. Immunol. Rev. 246:77-94. http://dx.doi.org/10.1111/j.1600-065X.2012.01098.x.
27. Lin R, Heylbroeck C, Pitha PM, Hiscott J. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-2996.
28. Hess J, Angel P, Schorpp-Kistner M. 2004. AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci. 117:5965-5973. http://dx.doi.org/10 .1242/jcs.01589.
29. Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M, Angel P. 2002. Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB.EMBOJ. 21:6321-6329. http://dx.doi .org/10.1093/emboj/cdf648.
30. Meixner A, Karreth F, Kenner L, Wagner EF. 2004. JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J. 23:1325-1335. http://dx.doi.org/10.1038/sj.emboj.7600133.
31. Williams SC, Cantwell CA, Johnson PF. 1991. A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro. Genes Dev. 5:1553-1567. http://dx.doi.org/10.1101/gad.5.9.1553.
32. Poli V. 1998. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J. Biol. Chem. 273:29279-29282. http://dx.doi.org/10.1074/jbc.273.45.29279.
33. Lu Y-C, Kim I, Lye E, Shen F, Suzuki N, Suzuki S, Gerondakis S, Akira S, Gaffen SL, Yeh W-C, Ohashi PS. 2009. Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J. Immunol. 182:7212-7221. http://dx.doi.org/10.4049/jimmunol .0802971.
34. Zhang Z, Bryan JL, DeLassus E, Chang L-W, Liao W, Sandell LJ. 2010. CCAAT/enhancer-binding protein {beta} and NF-{kappa}B mediate high level expression of chemokine genes CCL3 and CCL4 by human chondrocytes in response to IL-1{beta}. J. Biol. Chem. 285:33092-33103. http://dx .doi.org/10.1074/jbc.M110.130377.
35. John AE, Zhu YM, Brightling CE, Pang L, Knox AJ. 2009. Human airway smooth muscle cells from asthmatic individuals have CXCL8 hypersecretion due to increased NF-kappa B p65, C/EBP beta, and RNA polymerase II binding to the CXCL8 promoter. J. Immunol. 183:4682-4692. http://dx.doi.org/10.4049/jimmunol.0803832.
36. Haim K, Weitzenfeld P, Meshel T, Ben-Baruch A. 2011. Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Neoplasia 13:230-243.
37. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. 2012. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142:978-988. http://dx.doi.org/10.1053/j .gastro.2011.12.055.
38. Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F. 2011. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One 6:e21381. http://dx.doi.org/10 .1371/journal.pone.0021381.
39. Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, Beard MR. 2009. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J. Virol. 83:836-846. http://dx.doi.org/10.1128/JVI .01388-08.
40. Akbar H, Idrees M, Butt S, Awan Z, Sabar MF, Rehaman IU, Hussain A, Saleem S. 2011. High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients. Infect. Genet. Evol. 11:1301-1305. http://dx.doi.org/10 .1016/j.meegid.2011.04.021.
41. Casola A, Garofalo RP, Jamaluddin M, Vlahopoulos S, Brasier AR. 2000. Requirement of a novel upstream response element in respiratory syncytial virus-induced IL-8 gene expression. J. Immunol. 164:5944-5951.
42. Koetzler R, Zaheer RS, Wiehler S, Holden NS, Giembycz MA, Proud D. 2009. Nitric oxide inhibits human rhinovirus-induced transcriptional activation of CXCL10 in airway epithelial cells. J. Allergy Clin. Immunol. 123:201-208.e9. http://dx.doi.org/10.1016/j.jaci.2008.09.041.
43. Veckman V, Osterlund P, Fagerlund R, Melén K, Matikainen S, Julkunen I. 2006. TNF-alpha and IFN-alpha enhance influenza-A-virusinduced chemokine gene expression in human A549 lung epithelial cells. Virology 345:96-104. http://dx.doi.org/10.1016/j.virol.2005.09.043.
44. Brownell J, Wagoner J, Lovelace ES, Thirstrup D, Mohar I, Smith W, Giugliano S, Li K, Crispe IN, Rosen HR, Polyak SJ. 2013. Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J. Hepatol. 59:701-708. http://dx.doi.org/10.1016/j.jhep.2013.06.001.
45. Li K, Chen Z, Kato N, Gale M, Lemon SM. 2005. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J. Biol. Chem. 280:16739-16747. http://dx.doi.org/10 .1074/jbc.M414139200.
46. Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, Li K. 2009. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 83:9824-9834. http://dx.doi.org/10.1128/JVI.01125-09.
47. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 102:9294-9299. http://dx.doi.org/10.1073/pnas.0503596102.
48. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich H-G, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. http://dx.doi.org/10.1038/nm1268.
49. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ, Elledge SJ. 2009. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl. Acad. Sci. U.S.A. 106:16410-16415. http://dx .doi.org/10.1073/pnas.0907439106.
50. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81:7749-7758. http://dx.doi.org/10.1128/JVI.02438-06.
51. Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, Wakita T, Meurs EF. 2011. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7:e1002289. http://dx .doi.org/10.1371/journal.ppat.1002289.
52. Alcamí A, Symons JA, Smith GL. 2000. The vaccinia virus soluble alpha/ beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74:11230-11239. http://dx.doi .org/10.1128/JVI.74.23.11230-11239.2000.
53. Schnell G, Loo Y-M, Marcotrigiano J, Gale M. 2012. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog. 8:e1002839. http://dx.doi.org/10.1371/journal.ppat .1002839.
54. Lu X, Masic A, Liu Q, Zhou Y. 2011. Regulation of influenza A virus induced CXCL-10 gene expression requires PI3K/Akt pathway and IRF3 transcription factor. Mol. Immunol. 48:1417-1423. http://dx.doi.org/10 .1016/j.molimm.2011.03.017.
55. Sachdeva M, Liu Q, Cao J, Lu Z, Mo Y-Y. 2012. Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res. 40:6683-6692. http://dx.doi.org/10.1093/nar/gks324.
56. Ghosh AK, Bhattacharyya S, Mori Y, Varga J. 2006. Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/ enhancer binding protein beta (C/EBPbeta). J. Cell. Physiol. 207:251-260. http://dx.doi.org/10.1002/jcp.20559.
57. Sirianni R, Nogueira E, Bassett MH, Carr BR, Suzuki T, Pezzi V, Andò S, Rainey WE. 2010. The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. J. Cell Sci. 123: 3956-3965. http://dx.doi.org/10.1242/jcs.055806.
58. Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. 2010. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50:1-14. http://dx.doi.org/10.1016/j.cyto.2009.11.021.
59. Luster AD, Ravetch JV. 1987. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J. Exp. Med. 166:1084-1097. http://dx.doi.org/10.1084/jem.166.4.1084.
60. Ho L-J, Hung L-F, Weng C-Y, Wu W-L, Chou P, Lin Y-L, Chang D-M, Tai T-Y, Lai J-H. 2005. Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J. Immunol. 174:8163-8172.
61. Di Domizio J, Blum A, Gallagher-Gambarelli M, Molens J-P, Chaperot L, Plumas J. 2009. TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood 114:1794-1802. http://dx.doi.org/10.1182/blood-2009-04-216770.
62. Heim MH. 2013. Innate immunity and HCV. J. Hepatol. 58:564-574. http://dx.doi.org/10.1016/j.jhep.2012.10.005.
63. Girard S, Vossman E, Misek DE, Podevin P, Hanash S, Bréchot C, Beretta L. 2004. Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology 40:708-718. http://dx.doi.org/10.1002/hep.20371.
64. Raychoudhuri A, Shrivastava S, Steele R, Dash S, Kanda T, Ray R, Ray RB. 2010. Hepatitis C virus infection impairs IRF-7 translocation and alpha interferon synthesis in immortalized human hepatocytes. J. Virol. 84:10991-10998. http://dx.doi.org/10.1128/JVI.00900-10.
65. Inoue K, Tsukiyama-Kohara K, Matsuda C, Yoneyama M, Fujita T, Kuge S, Yoshiba M, Kohara M. 2012. Impairment of interferon regulatory factor-3 activation by hepatitis C virus core protein basic amino acid region 1. Biochem. Biophys. Res. Commun. 428:494-499. http://dx.doi .org/10.1016/j.bbrc.2012.10.079.